315 results on '"Dahl, M.-L."'
Search Results
2. Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity
3. Disposition of the Neuroleptics Perphenazine, Zuclopenthixol, and Haloperidol Cosegregates with Polymorphic Debrisoquine Hydroxylation
4. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients
5. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients
6. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests) : focus on antidepressants
7. Men´s experiences of using anabolic androgenic steroids
8. Taurine in plasma and CSF: a study in healthy male volunteers
9. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
10. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism
11. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses
12. Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes
13. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
14. A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age
15. FMO3 polymorphisms in 13 ethnic populations: frequency and linkage analysis: YSF-57
16. Debrisoquine and S -mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia
17. In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans
18. Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin
19. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype
20. Pharmacogenomics as a tool for tailored therapy: 187
21. Apo-E genotype and donepezil therapeutic outcome in patients with Alzheimerʼs disease: 148
22. Genetic polymorphisms of CYP2C8 and CYP2C9 influence diurnal blood pressure parameters in elderly subjects: 147
23. A PK-PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy
24. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone
25. Polymorphic 2-hydroxylation of desipramine: A population and family study
26. Pharmacokinetics of methylphenidate in plasma, exhaled breath, oral fluid and dried blood spots after a single oral dose of ritalin 20 mg
27. Nonlinearity of amoxicillin absorption kinetics in human
28. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
29. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians
30. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages
31. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
32. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
33. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors
34. Paroxetine withdrawal syndrome in a neonate
35. Pharmacogenetics of antidepressants: clinical aspects
36. Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship?
37. Debrisoquin and S-Mephenytoin Hydroxylation Phenotypes and CYP2D6 Genotypes in an Estonian Population
38. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
39. Genetic polymorphisms of CYP2C8 and CYP2C9 influence diurnal blood pressure parameters in elderly subjects
40. Farmakogenetiska faktorer som influerar plasmanivåerna av risperidon och dess aktiva metabolit
41. Impact of CYP3A4 polymorphisms on donepezil plasma levels and therapeutic outcome
42. Impact of CYP3A4 and CYP3A5 polymorphisms on clinical outcome of donepezil in Alzheimer’s disease patients
43. Impact of Apo-E genotype on the response to donepezil therapy in patients with Alzheimer’s Disease
44. Dopamine D2 and D3 receptor gene polymorphisms and clinical outcome of risperidone therapy in schizophrenic patients
45. Serotonin 2C receptor gene polymorphisms in association with extrapyramidal side-effects in schizophrenic patients
46. The effect of maternal canthaxanthin supplementation and hen age on breeder performance, early chick traits, and indices of innate immune function.
47. Clinical impact of CYP2D6 polymorphism in patients with Alzheimer's disease in therapy with donepezil
48. Clinical impact of 5-HT2A polymorphisms on risperidone therapeutic outcome in schizophrenic patients
49. Effects of CYP3A4 interacting drugs on donepezil plasma levels in patients with Alzheimer’s disease
50. Impact of CYP2D6 polymorphism on plasma levels of donepezil: clinical relevance in patients with Alzheimer’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.